A130 SAFETY OF COMBINATION BIOLOGIC AND ANTI-REJECTION THERAPY POST-LIVER TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: LONDON ONTARIO EXPERIENCE

BACKGROUND: Despite anti-rejection immunosuppressive therapies post-liver transplantation (LT), patients with concurrent inflammatory bowel disease (IBD) may have persistent bowel inflammation that requires addition of biologic therapy. AIMS: To evaluate the safety of combination biologic and anti-r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Can Assoc Gastroenterol
Autors principals: Al Draiweesh, S, Ma, C, Alkhattabi, M, McDonald, C, Chande, N, Feagan, B G, Gregor, J C, Khanna, R, Marotta, P, Sandhu, A S, Qumosani, K, Teriaky, A, Brahmania, M, Jairath, V
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Posters Of Distinction
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512649/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.129
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars